MapLight Therapeutics, Inc. (MPLT) Income Statement
MPLT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMPLT revenue and net income
MPLT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MPLT quarterly EPS vs estimates
MapLight Therapeutics beat the analyst EPS estimate in 1 of the last 5 quarters. Next report: December 3, 2026 (estimate $-1.22).
MPLT income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $578,000 | $701,000 | $556,000 | $574,000 |
| Gross profit | −$578,000 | −$701,000 | −$556,000 | −$574,000 |
| Research & development | $137.8M | $67.8M | $49.1M | $26.6M |
| Sales, general & admin | $30.7M | $14.4M | $7.6M | $4.1M |
| Total operating expenses | $168.5M | $82.2M | $56.7M | $30.7M |
| Operating income | −$169.1M | −$82.9M | −$57.3M | −$31.2M |
| Interest income | $5.5M | — | — | — |
| Income before taxes | −$161.2M | −$77.6M | −$55.7M | −$30.0M |
| Net income | −$161.2M | −$77.6M | −$55.7M | −$30.0M |
| EBITDA | −$160.6M | −$76.9M | −$55.2M | −$29.4M |
| EPS (diluted) | −$78.76 | −$1.87 | −$1.34 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $147,000 | $162,000 | $140,000 | $136,000 | $136,000 | $166,000 | — | — | $173,000 | $147,000 | $128,000 |
| Gross profit | −$147,000 | −$162,000 | −$140,000 | −$136,000 | −$136,000 | −$166,000 | — | — | −$173,000 | −$147,000 | −$128,000 |
| Research & development | $53.4M | $53.7M | $64.5M | $27.1M | $26.7M | $19.6M | $20.7M | $16.8M | $15.5M | $15.2M | $10.4M |
| Sales, general & admin | $10.1M | $10.8M | $18.8M | $4.4M | $3.8M | $3.8M | $2.1M | $4.1M | $4.3M | $3.9M | $1.6M |
| Total operating expenses | $63.4M | $64.3M | $83.2M | $31.5M | $30.5M | $23.4M | $22.8M | $20.9M | $19.8M | $19.1M | $12.0M |
| Operating income | −$63.5M | −$64.5M | −$83.4M | −$31.5M | −$30.7M | −$23.5M | −$22.8M | −$20.9M | −$20.0M | −$19.3M | −$12.2M |
| Interest income | $2.3M | $2.5M | $2.5M | $1.5M | — | — | $899,000 | $1.1M | — | — | — |
| Income before taxes | −$60.2M | −$60.7M | −$79.5M | −$29.4M | −$29.8M | −$22.3M | −$21.2M | −$19.0M | −$18.4M | −$18.9M | −$12.0M |
| Net income | −$60.2M | −$60.7M | −$79.5M | −$29.4M | −$29.8M | −$22.3M | −$21.2M | −$19.0M | −$18.4M | −$18.9M | −$12.0M |
| EBITDA | −$63.4M | −$60.5M | −$79.4M | −$29.3M | −$29.7M | −$22.2M | −$21.0M | −$18.8M | −$18.2M | −$18.8M | −$11.9M |
| EPS (diluted) | −$1.32 | −$1.34 | −$2.47 | −$37.18 | −$39.11 | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MPLT's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MPLT financial results
MapLight Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $161.2 million. Diluted earnings per share came to −$78.76.
See the MPLT stock overview for the latest quote and news, or the MPLT chart for price history and technical indicators.
MPLT income statement FAQ
Does MapLight Therapeutics have revenue?
MapLight Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is MapLight Therapeutics profitable?
No. MapLight Therapeutics reported a net loss of $161.2 million in fiscal 2025.
How much does MapLight Therapeutics spend on research and development?
MapLight Therapeutics spent $137.8 million on research and development in fiscal 2025.
What are MapLight Therapeutics's earnings per share?
MapLight Therapeutics earned $-78.76 per diluted share in fiscal 2025, compared with $-1.87 a year earlier.
When will MapLight Therapeutics report its next earnings?
MapLight Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 3, 2026.
When does MapLight Therapeutics's fiscal year end?
MapLight Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.